Efficacy and safety of repeated infusion of levosimendan in outpatients with advanced heart failure: a real-world experience

Masarone, Daniele; Valente, Fabio; Verrengia, Marina; Ammendola, Ernesto; Gravino, Rita; D’Alterio, Giuliano; Petraio, Andrea; Pacileo, Giuseppe

doi:10.2459/jcm.0000000000000983

Cited by 13 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another strategy used in patients with advanced heart failure is the periodic infusion of levosimendan ( 19 ), which can lead to an improvement in the hemodynamic profile ( 20 ) and quality of life as well as reduction of acutely decompensated heart failure episodes in patients with advanced HFrEF ( 21 ). Pulsed levosimendan infusion can be performed at fixed intervals or by assessing changes in hemodynamic parameters ( 22 ), leading to a clear clinical benefit in both cases.…”

Section: Discussionmentioning

confidence: 99%

Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report

Masarone

Petraio

Fiorentino³

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

Cardiac contractility modulation (CCM) is a novel device-based therapy in patients with heart failure with reduced ejection fraction (HFrEF). In randomized clinical trials and real-life studies, CCM has been shown to improve exercise tolerance and quality of life, reverse left ventricular remodeling and reduce hospitalization in patients with HFrEF. In this case report, we describe for the first time the use of CCM as a “bridge to transplant” in a young obese patient with advanced heart failure due to non-ischemic dilated cardiomyopathy. The patient had a poor quality of life and frequent heart failure-related hospitalizations despite the optimal medical therapy and, due to obesity, a suitable heart donor was unlikely to be identified in the short term and due to severe obesity risk of complications after implantation of a left ventricular assist device (LVAD) was very high.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report

Masarone

Petraio

Fiorentino³

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Analyzing these data and some studies which indicate that some drugs such as ivabradine (I f channel inhibitor) [24]. bisoprolol (selective β 1 -blocker) [25], milrinone (phosphodiesterase-3 inhibitor) [26], and levosimendan (calcium sensitizer) [27] are used for the treatment of heart failure. In this study, the biological activity of these drugs against infarct area was evaluated to compare with effect produced by derivative of diazocine.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Biological Activity of a Diazocine Derivative against Heart Failure Using an Ischemia-Reperfusion Injury Model

et al. 2022

View full text Add to dashboard Cite

Background There are studies, which suggest that some diazocine derivatives can exert effects on the cardiovascular system; however, these effects are not very clear. Objective The aim of this research was to evaluate the biological activity of a diazocine derivative against heart failure translated as area infarct. Methods Biological activity produced by diazocine derivatives against heart failure was determinate using an ischemia/reperfusion injury model. Besides, to characterize the molecular mechanism of effect exerted by diazocine derivative on left ventricular pressure (LVP) was determinate in an isolated rat heart model using nifedipine, PINAME TXA2, and quinalizarin as controls. Results The results showed that diazocine derivative decrease the infarct area and increase the LVP. However, the effect produced by diazocine derivative on LVP was inhibited in the presence of quinalizarin. Conclusions The results indicate that biological activity produced by diazocine derivative on left ventricular pressure is through protein CK2 activation; this phenomenon could be translated as a decrease in both infarct area and heart failure.

show abstract

“…Levosimendan has a more prolonged pharmacological action (10-14 days) than other inotropic drugs, due to the long halflife (about 80 hours) of its active metabolite-OR1896. In clinical trials and a single-center study, ambulatory infusion of levosimendan improved functional capacity and quality of life and reduced hospitalizations in outpatients with advanced HFrEF [58,59] without an increase in arrhythmic burden. Moreover, an echocardiographic pilot study showed that 6 hours' infusion of levosimendan increased cardiac index and cardiac output and reduced left atrial pressure and pulmonary pressure in outpatients with AdvHF [60].…”

Section: Inotropesmentioning

confidence: 99%

Advanced heart failure: state of the art and future directions

Masarone¹,

Kittleson²,

Petraio³

et al. 2022

Rev. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

Advanced heart failure is a clinical challenge that requires a pathophysiological-based approach. As the field has been the subject of multiple reviews, the objective of this paper is not to duplicate these publications but rather to offer practical tips for the clinical cardiologist to enable the optimal management of patients with advanced heart failure. Advanced heart failure is defined as a clinical syndrome characterized by severe and persistent symptoms, most commonly with severe ventricular dysfunction, despite optimized medical therapy. This review covers the management of the advanced heart failure patient from pharmacologic therapy with diseasemodifying drugs, to the use of electrical therapy devices, percutaneous valve repair and finally to the role of left ventricular assist devices and heart transplantation. The review also explores future directions in the management of advanced heart failure, including translational perspectives for the treatment of this syndrome.

show abstract

Efficacy and safety of repeated infusion of levosimendan in outpatients with advanced heart failure: a real-world experience

Cited by 13 publications

References 10 publications

Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report

Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report

Evaluation of Biological Activity of a Diazocine Derivative against Heart Failure Using an Ischemia-Reperfusion Injury Model

Advanced heart failure: state of the art and future directions

Contact Info

Product

Resources

About